Dr Tomás Duraj | Part 1 Targeting Cancer Metabolism - Why Mitochondria Matter More Than Mutations

We’ve been told for decades that cancer is a genetic disease - a matter of unlucky mutations. But what if we’ve been starting in the wrong place?In this two-part episode, medical doctor and cancer metabolism researcher Dr. Tomás Duraj takes us through a paradigm-shifting look at cancer - exploring the metabolic theory, how it contrasts with the prevailing somatic mutation theory, and why mitochondrial dysfunction may hold the key to both treatment and prevention.This episode covers the history of cancer theory, the evolutionary biology behind it, and why current models might be missing the mark by focusing on downstream symptoms instead of upstream causes.In Part 1, we cover:🧬 The somatic mutation theory vs. the metabolic theory of cancer🧠 Why mitochondria may be the origin, not a side-effect📚 The history of cancer theory - and why we got stuck on genetics🧪 Redefining the Warburg effect and oxidative phosphorylation🧬 BRCA mutations, mitochondrial signalling & inherited risk⚡ Energy before all else - how bioenergetics impacts everything🍽️ Why dietary interventions (like ketogenic therapy) are still so misunderstood This conversation is foundational - if you want to understand why cancer research has been stalling (and where the future might be), this is where to start and end.🎙️ Stay tuned for Part 2, where Dr Tomás dives into the potential of metabolic therapies in real-life application and treatment frameworks.Mentioned in this episode:PublicationsBook - Tripping Over The Truth by Travis Christofferson Paper The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancerPaper - Successful application of dietary ketogenic metabolic therapy in patients with glioblastomaFind Dr Duraj:Website Ketogenic Metabolic Therapy ForumDr Seyfried’s lab at Boston CollegeDonate to the labWant to watch this on video? Subscribe on YouTubeInstagram  @degreesofhealthDisclaimer Hosted on Acast. See acast.com/privacy for more information.

There are no comments yet.

Please log in to write the first comment.